

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Keith D. ALLEN et al.

Application No.: 09/903,395

Filed: July 10, 2001

For: Transgenic Mice Containing Melanocortin-3 Receptor Gene

Disruptions

Examiner:

Unassigned

Art Unit:

1632

Atty. Docket No.: R-653

Confirmation No.: 9465

RECEIVED

NOV 1 4 7000

TECH CENTER 16

PRELIMINARY AMENDMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

11:

Prior to the examination of the above-referenced application and in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed October 3, 2002, entry of the following amendment is respectfully requested:

In the Drawings

Please replace Figure 2A in the application with the enclosed new Figure 2A.

REMARKS

The amendment to Figure 2A merely adds a sequence identifier to the figure to comply with 37 C.F.R. 1.821(d) and does not introduce new matter. Entry of the foregoing amendment is respectfully requested.

Favorable action on the merits is earnestly solicited.

Date: November 4, 2002

Respectfully submitted.

Johnst (Rg. No. 47,536)

for Jane K. Babin, Reg. No. 47,224

DELTAGEN, INC. 740 Bay Road Redwood City, CA 94063 (650) 569-5100

CERTIFICATION MADE

Sovember 4, 200.

Deberah A. Mojarro

Dampano

Date:

11/4/02

Signed